References
- Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34: 1251–1258
- Okongo M, Morgan D, Mayanja B, et al. Causes of death in a rural, population-based human immunodeficiency virus type 1 natural history cohort in Uganda. Int J Epidemiol 1998; 27: 698–702
- Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001; 43: 226–233
- Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001; 77: 769–773
- Ford BJ. AIDS and Africa. Biologist 2000; 47: 224
- Gangaidzo IT, Mielke J, Matenga JA. Ethical considerations in the care of the patient with HIV/AIDS. Cent Afr J Med 1999; 45: 51–53
- Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710–718
- Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741–745
- Larsen RA. Azoles and AIDS. J Infect Dis 1990; 162: 727–370
- Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992; 326: 83–89
- Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA. High-dose fluconazole for the treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994; 170: 238–242
- Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis 1998; 27: 260–264